1. Home
  2. MSGY vs SNOA Comparison

MSGY vs SNOA Comparison

Compare MSGY & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MSGY

Masonglory Limited Ordinary Shares

N/A

Current Price

$4.27

Market Cap

6.0M

Sector

N/A

ML Signal

N/A

Logo Sonoma Pharmaceuticals Inc.

SNOA

Sonoma Pharmaceuticals Inc.

N/A

Current Price

$1.16

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MSGY
SNOA
Founded
2018
1999
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
6.1M
IPO Year
2024
2006

Fundamental Metrics

Financial Performance
Metric
MSGY
SNOA
Price
$4.27
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.2M
42.8K
Earning Date
07-30-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.26
EPS
★ N/A
N/A
Revenue
N/A
★ $19,529,000.00
Revenue This Year
N/A
$22.44
Revenue Next Year
N/A
$12.73
P/E Ratio
$5.89
★ N/A
Revenue Growth
N/A
★ 36.68
52 Week Low
$0.23
$0.85
52 Week High
$11.42
$4.30

Technical Indicators

Market Signals
Indicator
MSGY
SNOA
Relative Strength Index (RSI) 55.44 36.87
Support Level $0.85 $1.03
Resistance Level $5.88 $1.25
Average True Range (ATR) 1.62 0.06
MACD 0.09 -0.01
Stochastic Oscillator 25.39 15.00

Price Performance

Historical Comparison
MSGY
SNOA

About MSGY Masonglory Limited Ordinary Shares

Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.

About SNOA Sonoma Pharmaceuticals Inc.

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Share on Social Networks: